litlas
Log inCreate account

Kim Margolin

Active 1985–2025

118
Papers
30,075
Citations
82
h-index
113
i10-index

Citations

Citations per year for Kim Margolin1984: 1 citations1985: 1 citations1987: 3 citations1988: 1 citations1989: 4 citations1990: 8 citations1991: 17 citations1992: 20 citations1993: 38 citations1994: 14 citations1995: 21 citations1996: 10 citations1997: 20 citations1998: 22 citations1999: 16 citations2000: 23 citations2001: 36 citations2002: 83 citations2003: 75 citations2004: 99 citations2005: 74 citations2006: 98 citations2007: 151 citations2008: 131 citations2009: 171 citations2010: 153 citations2011: 140 citations2012: 156 citations2013: 155 citations2014: 162 citations2015: 272 citations2016: 427 citations2017: 461 citations2018: 392 citations2019: 1,143 citations2020: 1,216 citations2021: 1,095 citations2022: 802 citations2023: 660 citations2024: 1,035 citations2025: 503 citations2026: 15 citations1986: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,265 citing papers, 30.9% of this breakdownChina: 1,200 citing papers, 8.7% of this breakdownGermany: 779 citing papers, 5.7% of this breakdownItaly: 759 citing papers, 5.5% of this breakdownUnited Kingdom: 687 citing papers, 5% of this breakdownFrance: 650 citing papers, 4.7% of this breakdownAustralia: 489 citing papers, 3.5% of this breakdownNetherlands: 476 citing papers, 3.5% of this breakdownCanada: 447 citing papers, 3.2% of this breakdownSpain: 430 citing papers, 3.1% of this breakdownSwitzerland: 375 citing papers, 2.7% of this breakdownJapan: 286 citing papers, 2.1% of this breakdown
0%30.9%Other 21.4%

Institutions

Fields

  • Medicine70.2%
  • Biochemistry, Genetics and Molecular Biology14.2%
  • Immunology and Microbiology12%
  • Engineering1.1%
  • Neuroscience0.6%
  • Materials Science0.3%
  • Other1.6%

Topics

  • Cancer Immunotherapy and Biomarkers13.6%
  • Immunotherapy and Immune Responses8.2%
  • CAR-T cell therapy research6.5%
  • Brain Metastases and Treatment3.6%
  • Immune Cell Function and Interaction3.4%
  • Melanoma and MAPK Pathways3.2%
  • Other61.5%

Coauthors

All papers

Open in search
  1. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

    Authors: Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom, Siwen Hu‐Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach‐Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari Kendra, Richard C. Wu, Craig Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas - New England Journal of Medicine 2023 cited by 827

  2. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

    Authors: Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M. Awad, Matthew D. Hellmann, Jessica J. Lin, Terence W. Friedlander, Meghan E. Bushway, Kristen N. Balogh, Tracey Sciuto, Victoria Kohler, Samantha Jane Turnbull, Rana H. Besada, Riley R. Curran, Benjamin Trapp, Julian Scherer, Asaf Poran, Dewi Harjanto, Dominik Barthelme, Ying S. Ting, Jesse Z. Dong, Yvonne Ware, Yu-Ting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan - Cell 2020 cited by 763

  3. Response assessment criteria for brain metastases: proposal from the RANO group

    Authors: Nancy U. Lin, Eudocia Q. Lee, Hidefumi Aoyama, Igor J. Barani, Daniel P. Barboriak, Brigitta G. Baumert, Martin Bendszus, Paul D. Brown, D. Ross Camidge, Susan M. Chang, Janet Dancey, Elisabeth G.E. de Vries, Laurie E. Gaspar, Gordon J. Harris, F. Stephen Hodi, Steven N. Kalkanis, Mark E. Linskey, David Macdonald, Kim Margolin, Minesh P. Mehta, David Schiff, Riccardo Soffietti, John H. Suh, Martin J. van den Bent, Michael A. Vogelbaum, Patrick Y. Wen - The Lancet Oncology 2015 cited by 1,088

  4. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Authors: Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok - Journal of Clinical Oncology 2015 cited by 2,122

  5. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Authors: Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin - New England Journal of Medicine 2018 cited by 1,321

  6. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

    Authors: Ari M. Vanderwalde, Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey A. Sosman, Alexandra P. Ikeguchi, Adrienne I. Victor, Thach‐Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu‐Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu, Antoni Ribas - Nature Medicine 2023 cited by 167

  7. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

    Authors: Michael B. Atkins, Michael T. Lotze, Janice P. Dutcher, Richard I. Fisher, Geoffrey R. Weiss, Kim Margolin, Jeff Abrams, Mario Sznol, David Parkinson, Michael Hawkins, Carolyn Paradise, Lori Kunkel, Steven A. Rosenberg - Journal of Clinical Oncology 1999 cited by 2,034

  8. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Authors: Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Ragini R. Kudchadkar, Natalie Miller, Lakshmanan Annamalai, Sneha Berry, Elliot Chartash, Adil Daud, Steven P. Fling, Philip Friedlander, Harriet M. Kluger, Holbrook E. Kohrt, Lisa Lundgren, Kim Margolin, Alan Mitchell, Thomas Olencki, Drew M. Pardoll, Sunil Reddy, Erica Shantha, William H. Sharfman, Elad Sharon, Lynn Shemanski, Michi M. Shinohara, Joel Sunshine, Janis M. Taube, John A. Thompson, Steven M. Townson, Jennifer H. Yearley, Suzanne L. Topalian, Martin A. Cheever - New England Journal of Medicine 2016 cited by 1,243

  9. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Authors: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 cited by 1,564

  10. Cytokines in Cancer Immunotherapy

    Authors: Sylvia Lee, Kim Margolin - Cancers 2011 cited by 683

  11. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

    Authors: Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve M. Boland, Bartosz Chmielowski, Dominick J. DiMaio, Alison B. Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth F. Grossmann, Samantha Guild, Ashley M. Holder, Douglas B. Johnson, Richard W. Joseph, Giorgos C. Karakousis, Kari Kendra, Julie R. Lange, Ryan M. Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K.S. Salama, Rohit Sharma, Joseph J. Skitzki, Jeffrey A. Sosman, Evan Wuthrick, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2021 cited by 337

  12. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Margolin, Elizabeth R. Plimack, Alexandre Lambert, Ian M. Waxman, Hans J. Hammers - Journal of Clinical Oncology 2014 cited by 1,078

  13. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

    Authors: Kim Margolin, Marc S. Ernstoff, Omid Hamid, Donald P. Lawrence, David F. McDermott, Igor Puzanov, Jedd D. Wolchok, Joseph I. Clark, Mario Sznol, Theodore F. Logan, Jon Richards, Tracy Michener, Ágnes Balogh, Kevin N. Heller, F. Stephen Hodi - The Lancet Oncology 2012 cited by 1,081

  14. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

    Authors: Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Phillip Friedlander, Adil Daud, Harriet M. Kluger, Sunil Reddy, Brian C. Boulmay, Adam I. Riker, Melissa Burgess, Brent A. Hanks, Thomas Olencki, Kim Margolin, Lisa Lundgren, Abha Soni, Nirasha Ramchurren, Candice D. Church, Song Y. Park, Michi M. Shinohara, Bob Salim, Janis M. Taube, Steven Bird, Nageatte Ibrahim, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian - Journal of Clinical Oncology 2019 cited by 390

  15. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

    Authors: Rodabe N. Amaria, Alexander M. Menzies, Elizabeth M. Burton, Richard A. Scolyer, Michael T. Tetzlaff, Robert Antdbacka, Charlotte E. Ariyan, Roland L. Bassett, Brett Carter, Adil Daud, Mark B. Faries, Leslie A. Fecher, Keith T. Flaherty, Jeffrey E. Gershenwald, Omid Hamid, Angela Hong, John M. Kirkwood, Serigne Lo, Kim Margolin, Jane L. Messina, Michael A. Postow, Helen Rizos, Merrick I Ross, Elisa A. Rozeman, Robyn P.M. Saw, Vernon K. Sondak, Ryan J. Sullivan, Janis M. Taube, John F. Thompson, Bart A. van de Wiel, Alexander M.M. Eggermont, Michael A. Davies, Miles C. Andrews, Donald A. Berry, Matthew S. Block, Genevieve M. Boland, Kathryn Bollin, Matteo S. Carlino, Richard D. Carvajal, Jonathan Cohen, Diwakar Davar, Keith A. Delman, Reinhard Dummer, Michael D. Farwell, David E. Fisher, Alberto Fusi, Isabella C. Glitza, Tanja D. de Gruijl, David Gyorki, Axel Hauschild, Tina J. Hieken, James Larkin, David H. Lawson, Célèste Lebbé, Jeffrey E. Lee, Michael Lowe, Jason J. Luke, Grant A. McArthur, David F. McDermott, Jennifer L. McQuade, Tara C. Mitchell, Teresa M. Petrella, Peter A. Prieto, Igor Puzanov, Caroline Robert, April K.S. Salama, Shaneen Sandhu, Dirk Schadendorf, Alexander N. Shoushtari, Jeffrey A. Sosman, Susan M. Swetter, Ken K Tanabe, Samra Turajlic, Douglas S. Tyler, Scott E. Woodman, Frances C. Wright, Jonathan S. Zager, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Jennifer A. Wargo, Christian U. Blank, Hussein A. Tawbi, Georgina V. Long - The Lancet Oncology 2019 cited by 218

  16. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

    Authors: Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S. Miller, Sylvia M. Lee, Ann W. Silk, Shernan G. Holtan, Andreanne M. Lacroix, Steven P. Fling, Judith C. Kaiser, Jack O. Egan, Monica Jones, Peter R. Rhode, Amy D. Rock, Martin A. Cheever, Hing C. Wong, Marc S. Ernstoff - Clinical Cancer Research 2018 cited by 206

  17. Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

    Authors: Pavlina Chuntova, Frances Chow, Payal Watchmaker, Mildred Galvez, Amy B. Heimberger, Evan W. Newell, Aarón Díaz, Ronald A. DePinho, Ming O. Li, E. John Wherry, Duane A. Mitchell, Masaki Terabe, Derek A. Wainwright, Jay A. Berzofsky, Christel Herold‐Mende, James R. Heath, Michael Lim, Kim Margolin, E. Antonio Chiocca, Noriyuki Kasahara, Benjamin M. Ellingson, Christine E. Brown, Yvonne Chen, Peter E. Fecci, David A. Reardon, Gavin P. Dunn, Linda M. Liau, J Costello, Wolfgang Wick, Timothy F. Cloughesy, William C. Timmer, Patrick Y. Wen, Robert M. Prins, Michael Platten, Hideho Okada - Neuro-Oncology 2020 cited by 93

  18. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

    Authors: Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon, Apostolia M. Tsimberidou, Andrea J. Bullock, Breelyn A. Wilky, Jonathan C. Trent, Kim Margolin, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Bruno Bockorny, Justin C. Moser, Joseph E. Grossman, W.I. Ortuzar Feliu, Katherine Rosenthal, Steven O’Day, Heinz‐Josef Lenz, Benjamin L. Schlechter - Journal of Clinical Oncology 2023 cited by 55

  19. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities

    Authors: Michelle M. Kim, Minesh P. Mehta, Dee Dee Smart, Patricia S. Steeg, Julie A. Hong, Michael Graham Espey, Pataje G.S. Prasanna, Laura Crandon, Christine Hodgdon, Niki Kozak, Terri S. Armstrong, Aki Morikawa, Nicole E. Willmarth, Kirk Tanner, Adrienne Boire, Melanie Hayden Gephart, Kim Margolin, Jona A. Hattangadi‐Gluth, Hussein A. Tawbi, Daniel M. Trifiletti, Caroline Chung, Upal Basu-Roy, Robyn Burns, Isabella C. Glitza Oliva, Ayal A. Aizer, Carey K. Anders, Joanne Davis, Manmeet S. Ahluwalia, Veronica Chiang, Jing Li, Rupesh Kotecha, Silvia C. Formenti, Benjamin M. Ellingson, Vinai Gondi, Paul W. Sperduto, Jill S. Barnholtz‐Sloan, Jordi Rodón, Eudocia Q. Lee, Mustafa Khasraw, D.N. Yeboa, Priscilla K. Brastianos, Evanthia Galanis, C. Norman Coleman, Mansoor M. Ahmed - The Lancet Oncology 2023 cited by 39

  20. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

    Authors: David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffrey R. Weiss, Theodore F. Logan, John M. Kirkwood, Michael S. Gordon, Jeffrey A. Sosman, Marc S. Ernstoff, Christopher Tretter, Walter J. Urba, John W. Smith, Kim Margolin, James W. Mier, Jared Gollob, Janice P. Dutcher, Michael B. Atkins - Journal of Clinical Oncology 2004 cited by 819

  21. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

    Authors: Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine I. Rizzo, Kim Margolin - Neuro-Oncology 2021 cited by 125

  22. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

    Authors: Grant A. McArthur, Michele Maio, Ana Arance, Paul Nathan, Christian U. Blank, Marie‐Françoise Avril, Claus Garbe, Axel Hauschild, Dirk Schadendorf, Omid Hamid, Michael Fluck, Melissa S. Thebeau, Jacob Schachter, Richard Kefford, Marc C. Chamberlain, Martina Makrutzki, Susan Robson, René González, Kim Margolin - Annals of Oncology 2016 cited by 246

  23. Updates in the management of brain metastases

    Authors: Nils D. Arvold, Eudocia Q. Lee, Minesh P. Mehta, Kim Margolin, Brian M. Alexander, Nancy U. Lin, Carey K. Anders, Riccardo Soffietti, D. Ross Camidge, Michael A. Vogelbaum, Ian F. Dunn, Patrick Y. Wen - Neuro-Oncology 2016 cited by 284

  24. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

    Authors: Brendan D. Curti, Jon Richards, John Hyngstrom, Gregory A. Daniels, Mark B. Faries, Lynn G. Feun, Kim Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H.I. Andtbacka - Journal for ImmunoTherapy of Cancer 2022 cited by 29